PFT-001

PFT-001 is a preclinical RNA-based therapeutic candidate being developed by Pathfinder Therapeutics for the treatment of cancer. As the lead asset in the company's pipeline, PFT-001 leverages a proprietary RNA platform designed to modulate disease-driving genetic pathways that are often difficult to address with traditional small molecules or monoclonal antibodies. Currently in the preclinical stage, the program is undergoing evaluation to characterize its efficacy, safety, and pharmacokinetic profile in various tumor models. While the specific molecular target and RNA subtype (such as mRNA, siRNA, or antisense) have not been publicly disclosed by the sponsor, the development of PFT-001 represents a core component of Pathfinder's strategy to utilize next-generation RNA modalities for oncological indications.